DelveInsight’s "Retinal Vein Occlusion Pipeline Insight 2025" report delivers an in-depth examination of more than 15 pharmaceutical organizations and their 15+ investigational therapies currently advancing within the Retinal Vein Occlusion (RVO) research and development landscape. The study encompasses comprehensive profiles of both clinical and preclinical pipeline assets, with thorough evaluation across product classification, stage of development, route of administration, and molecular type. It also identifies inactive or discontinued therapeutic programs within this area.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Retinal Vein Occlusion Treatment Landscape. Click here to read more @ Retinal Vein Occlusion Pipeline Outlook

Key Insights from the Retinal Vein Occlusion Pipeline Report

On October 3, 2025, EyeBiotech Ltd. initiated a multi-cohort study involving four patient groups, each randomized (1:1) to receive either a low or high dose of EYE103 through intravitreal (IVT) injection. A total of 40 participants per cohort will be enrolled, with sequential enrollment guided by the sponsor’s discretion.
According to DelveInsight’s findings, the Retinal Vein Occlusion market features over 15 active developers advancing novel therapeutic formulations.

Leading pharmaceutical participants include Kodiak Sciences, Hoffman-La-Roche, iRenix Medical Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, and Eyevensys.

Notable therapies in development encompass Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham Treatment, Macular Laser Photocoagulation, Faricimab, and others.

For comprehensive details on the latest Retinal Vein Occlusion drug launches, ongoing drug development activities, and recent news updates, please visit the full Retinal Vein Occlusion Ongoing Clinical Trial Analysis report available here @ Retinal Vein Occlusion Ongoing Clinical Trial Analysis. 

Retinal Vein Occlusion Overview

Retinal vein occlusion ranks as the second most common retinal vascular disorder, representing a leading cause of vision impairment among elderly individuals. It is categorized into two primary types: Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO). CRVO—resulting from thrombosis of the main retinal vein posterior to the lamina cribrosa—can be further subdivided into ischemic (nonperfused) and non-ischemic (perfused) forms.

Retinal Vein Occlusion Emerging Drug Candidates

KSI-301 (Kodiak Sciences):
A next-generation anti-VEGF biologic engineered for prolonged intraocular activity. KSI-301 aims to reduce treatment frequency while sustaining efficacy, thereby alleviating injection burden on patients and providers. The therapy is currently under Phase III evaluation for RVO.

601 (Sunshine Guojian Pharmaceutical):
A recombinant humanized anti-VEGF monoclonal antibody injection being studied for retinal conditions including age-related macular degeneration, diabetic macular edema, and RVO. It is presently undergoing Phase II clinical trials.

IBE-814 (Ripple Therapeutics):
Formulated to deliver consistent steroid dosing over six to nine months, IBE-814 seeks to enhance clinical benefits and minimize common steroid-related side effects. The RIPPLE-1 Phase II study evaluates safety and efficacy of differing IBE-814 IVT regimens for macular edema secondary to RVO.

Stay informed about the latest trends in the Retinal Vein Occlusion pipeline! Discover essential updates on therapeutic advancements and their potential impact on both patients and the healthcare sector by visiting @ Retinal Vein Occlusion Unmet Needs.

Retinal Vein Occlusion Pipeline Report Highlights

The report offers an analytical view of key pharmaceutical developers engaged in RVO therapy innovation, segmented by their developmental phase—early, mid, and late stages. It also maps each company’s active, inactive, and discontinued projects. Insights include investigational drug targeting, mechanisms of action, monotherapy versus combination therapy status, and molecular attributes.

Additionally, DelveInsight examines partnership structures, academic collaborations, licensing agreements, and capital investments propelling future RVO market expansions.

Enhance your understanding of the Retinal Vein Occlusion pipeline developments! Stay up-to-date with the latest advances in drug discovery and clinical research @ Retinal Vein Occlusion Market Drivers and Barriers, and Future Perspectives.

Retinal Vein Occlusion Companies Included

Entities leading research and pipeline activity include Kodiak Sciences, Hoffman-La-Roche, iRenix Medical Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, and Eyevensys.

Route of Administration

RVO pipeline products are classified by administration pathway:

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

Molecular Categories

Therapies are differentiated by molecule type:

• Monoclonal Antibody

• Peptide

• Polymer

• Small Molecule

• Gene Therapy

Scope of the Report

Coverage: Global
Companies Covered: Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Key Therapies: EYLEA (Aflibercept), Faricimab, Macular Laser Photocoagulation, and other emerging anti-VEGF and corticosteroid candidates.
Therapeutic Assessments: Conducted by product type (Mono, Combination, or Mixed), by clinical stage (Discovery to Phase III), and by route of administration.

Gain valuable insights into the factors driving the market, challenges faced, and future directions in treatment strategies by accessing the full analysis here @ Retinal Vein Occlusion Market Drivers and Barriers, and Future Perspectives.

Table of Contents

• Introduction

• Executive Summary

• Retinal Vein Occlusion: Overview

• Pipeline Therapeutics

• Therapeutic Assessment

• Late Stage Products (Phase III)

• KSI-301: Kodiak Sciences

• Mid Stage Products (Phase II)

• 601: Sunshine Guojian Pharmaceutical

• Early Stage Products (Phase I)

• MHU650: Novartis

• Inactive Products

• Retinal Vein Occlusion Key Companies

• Retinal Vein Occlusion Key Products

• Retinal Vein Occlusion- Unmet Needs

• Retinal Vein Occlusion- Market Drivers and Barriers

• Retinal Vein Occlusion- Future Perspectives and Conclusion

• Retinal Vein Occlusion Analyst Views

• Retinal Vein Occlusion Key Companies

• Appendix

About DelveInsight

DelveInsight is a global healthcare market intelligence and consulting firm offering extensive analytical capabilities across the life sciences spectrum. With expert researchers and a focus on clinical innovation, DelveInsight provides custom-tailored insights to enable strategic business decisions for pharmaceutical, biotech, and healthcare organizations worldwide.

Contact Us

Kanishk

kkumar@delveinsight.com